文献速递脊柱关节炎

抗CD74抗体在脊柱关节炎中的系统评价与荟萃分析

Anti-CD74 antibodies in spondyloarthritis: A systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2020-12-10

该系统评价与荟萃分析检索了截至2019年8月7日的PubMed、Web of Science和Medline数据库,最终纳入9项研究,评估脊柱关节炎患者抗CD74 IgG和IgA抗体水平及其诊断价值。结果显示,脊柱关节炎患者抗CD74 IgG和IgA抗体均显著升高(IgG:SMD=0.88,95%CI=0.55至1.21;IgA:SMD=0.98,95%CI=0.68至1.28),抗CD74 IgG的汇总灵敏度、特异度和SROC曲线下面积分别为0.61、0.90和0.8881,抗CD74 IgA分别为0.59、0.95和0.8671。抗CD74抗体可能成为脊柱关节炎诊断的生物标志物,但尚存许多未解问题。

要点

  • 脊柱关节炎患者抗CD74 IgG和IgA抗体水平均显著高于对照。
  • 抗CD74 IgG诊断脊柱关节炎的汇总灵敏度0.61、特异度0.90。
  • 抗CD74 IgA诊断脊柱关节炎的汇总灵敏度0.59、特异度0.95。

核心结论

  • 抗CD74 IgG和IgA抗体在脊柱关节炎患者中显著升高,提示对脊柱关节炎具有较高的诊断特异度。
  • 抗CD74抗体可能成为脊柱关节炎诊断的生物标志物,但许多开放问题仍待解决。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Web of Science和Medline数据库自建库至2019年8月7日的文献。
  • 共检索到55项研究,最终纳入9项研究进行分析。
  • 采用汇总标准均数差(SMD)及95%置信区间(CI)评估抗体水平差异,采用灵敏度、特异度和SROC曲线评估诊断价值,根据异质性选择固定效应或随机效应模型。

主要发现

  • 与匹配对照相比,脊柱关节炎患者抗CD74 IgG抗体显著升高(SMD=0.88,95%CI=0.55至1.21)。
  • 与匹配对照相比,脊柱关节炎患者抗CD74 IgA抗体显著升高(SMD=0.98,95%CI=0.68至1.28)。
  • 抗CD74 IgG抗体的汇总灵敏度为0.61,特异度为0.90,SROC曲线下面积为0.8881。
  • 抗CD74 IgA抗体的汇总灵敏度为0.59,特异度为0.95,SROC曲线下面积为0.8671。

关键数值与推荐

  • 抗CD74 IgG诊断脊柱关节炎的汇总灵敏度0.61、特异度0.90、SROC曲线下面积0.8881。
  • 抗CD74 IgA诊断脊柱关节炎的汇总灵敏度0.59、特异度0.95、SROC曲线下面积0.8671。
  • 抗CD74 IgG水平在脊柱关节炎与对照间差异的SMD=0.88,95%CI=0.55至1.21。
  • 抗CD74 IgA水平在脊柱关节炎与对照间差异的SMD=0.98,95%CI=0.68至1.28。

临床怎么用

  • 抗CD74抗体具有较高诊断特异度,可作为脊柱关节炎诊断的潜在辅助生物标志物。
  • 抗CD74抗体灵敏度中等,阴性结果不能排除脊柱关节炎,需结合临床特征和其他检查综合判断。

局限性

  • 最终仅纳入9项研究,证据数量有限。
  • 抗CD74抗体诊断脊柱关节炎仍存在许多开放问题,尚不能常规用于临床诊断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: There is still an unmet need for a simple and reliable biomarker for the diagnosis of spondyloarthritis. Recent studies indicated that anti-CD74 antibody could act as a biomarker for spondyloarthritis. Therefore, this review aims to evaluate the levels of anti-CD74 IgG and IgA antibodies in spondyloarthritis and the diagnostic value of anti-CD74 antibodies. METHODS: PubMed, Web of Science and Medline were comprehensively searched from inception to August 7th, 2019. The pooled standard mean difference (SMD) with 95% confidence interval (CI) was used to estimate the differences of the levels of anti-CD74 IgG and IgA antibodies between spondyloarthritis patients and controls. Sensitivity, specificity and summary receiver operating characteristics (SROC) curve were used for evaluating the diagnostic value of anti-CD74 antibodies. The use of fixed-effect or random-effects model depended on heterogeneity. RESULTS: Among 55 searched studies, 9 studies were finally included for analysis. Anti-CD74 IgG and IgA antibodies were both significantly increased in spondyloarthritis patients compared with matched controls (IgG: SMD = 0.88, 95% CI = 0.55 to 1.21; IgA: SMD = 0.98, 95% CI = 0.68 to 1.28). The pooled sensitivity, specificity and area under the SROC curve of anti-CD74 IgG antibodies were 0.61, 0.90 and 0.8881, while these indicators of anti-CD74 IgA antibodies were 0.59, 0.95 and 0.8671, respectively. CONCLUSION: Anti-CD74 IgG and IgA antibodies were significantly increased in spondyloarthritis patients and suggest a high diagnostic specificity of spondyloarthritis. Anti-CD74 antibody could potentially be a biomarker for the diagnosis of spondyloarthritis, but many open questions remain.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Xu S, Zhang X, Chen Y, et al. Anti-CD74 antibodies in spondyloarthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2020. PMID: 33340822. doi:10.1016/j.semarthrit.2020.12.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。